Amamentação: transição alimentar durante a guerra espanhola e o período pós-guerra (1936-1949)

Durante los años 1900 hasta 1936, la salud infantil comenzaba a ganar importancia en Europa. En España, la mortalidad infantil era elevada. Para contrarrestar esta situación, el estado propuso medidas sanitarias, educativas y alimentarias. Objetivo. Analizar la Guerra Civil Española (1936-1939), que continuó con los “años del hambre” durante la posguerra (1939-1949), conocidos por el racionamiento de alimentos y decadencia de la salud materno-infantil. Método. Estudio histórico descriptivo con fuentes primarias y secundarias. Que trata sobre, el contexto sociosanitario y la transición alimentaria, que vivieron los infantes durante la guerra y posguerra española (1936-1949). Resultados. El gobierno realizó una promoción de la lactancia materna guiada por pediatras de la época, no obstante, la leche de fórmula ganó importancia, debido a la modificación de la estructura familiar básica. La figura clásica de la mujer se fracturó, en favor del trabajo en las fábricas o, en última instancia, como participantes activas en la guerra. Conclusiones. Las instituciones sanitarias, se centraron en el cuidado de heridos, cuestión que repercutió en la atención del niño enfermo. Esta situación dio lugar a altas tasas de morbimortalidad infantil, las cuales se mantuvieron hasta el final de la posguerra.During the years 1900 to 1936, children’s health began to gain importance in Europe. In Spain, infant mortality was high. To counteract this situation, the state proposed health, educational and food measures. Objective. To analyze the Spanish Civil War (1936-1939), which continued with the “hungry years” of the post-war period (1939-1949), known for food rationing and the decline of mother and child health. Method. Historical descriptive study with primary and secondary sources. It deals with the socio-health context and the food transition experienced by infants during the Spanish war and post-war period (1936-1949). Results. The government carried out a promotion of breastfeeding guided by pediatricians of the time, however, formula gained importance, due to the modification of the basic family structure. The classic figure of the woman was fractured, in favour of working in factories or, ultimately, as active participants in the war. Conclusions. Health institutions focused on the care of the wounded, an issue that impacted on the care of the sick child. This situation resulted in high rates of child morbidity and mortality, which continued until the end of the post-war period.Durante os anos de 1900 a 1936, a saúde das crianças começou a ganhar importância na Europa. Em Espanha, a mortalidade infantil foi elevada. Para contrariar esta situação, o Estado propôs medidas sanitárias, educativas e alimentares. Objectivo. Analisar a Guerra Civil Espanhola (1936-1939), que continuou com os “anos de fome” do pós-guerra (1939-1949), conhecida pelo racionamento de alimentos e pelo declínio da saúde materna e infantil. Método. Estudo descritivo histórico com fontes primárias e secundárias. Trata do contexto sócio-sanitário e da transição alimentar vivida pelos bebés durante a guerra espanhola e o período pós-guerra (1936-1949). Resultados. O governo realizou uma promoção da amamentação orientada por pediatras da época, mas a fórmula ganhou importância, devido à modificação da estrutura básica da família. A figura clássica da mulher foi fracturada, a favor de trabalhar em fábricas ou, em última análise, como participante activa na guerra. Conclusões. As instituições de saúde concentraram-se no cuidado dos feridos, uma questão que teve impacto no cuidado da criança doente. Esta situação resultou em elevadas taxas de morbilidade e mortalidade infantil, que se mantiveram até ao final do período pós-guerra

Producto alimenticio en forma de salsa tipo mayonesa y procedimiento de preparación

Producto alimenticio en forma de salsa tipo mayonesa y procedimiento de preparación. Salsa tipo mayonesa en cuya composición se incluye como emulsionante exclusivamente suero de mantequilla. Los restantes componentes son los habitualmente utilizados en este tipo de productos, como aceite vegetal, agua, vinagre de vino, azúcar, sal, zumo de limón, conservante y, opcionalmente, colorante y estabilizante. El procedimiento de preparación del producto se lleva a cabo en un equipo mezclador rotatorio siguiendo un orden determinado de adición de dichos componentes. El producto obtenido es estable al menos 16 meses a temperatura ambiente o mantenido en frío a 4◦C.Españ

Producto alimenticio en forma de salsa tipo mayonesa y procedimiento de preparación

Solicitud de patente (concesión en curso).-- Referencia OEPM: P200600466.-- Fecha de presentación: 22/02/2006.-- Solicitantes: Universidad de Sevilla (US), Corporación Alimentaria Peñasanta, S.A., Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Huelva.Salsa tipo mayonesa en cuya composición se incluye como emulsionante exclusivamente suero de mantequilla. Los restantes componentes son los habitualmente utilizados en este tipo de productos, como aceite vegetal, agua, vinagre de vino, azúcar, sal, zumo de limón, conservante y, opcionalmente, colorante y estabilizante. El procedimiento de preparación del producto se lleva a cabo en un equipo mezclador rotatorio siguiendo un orden determinado de adición de dichos componentes. El producto obtenido es estable al menos 16 meses a temperatura ambiente o mantenido en frío a 4°C.Peer reviewe

Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

Abstract Background Convalescent plasma has been widely used to treat COVID-19 and is under investigation in numerous randomized clinical trials, but results are publicly available only for a small number of trials. The objective of this study was to assess the benefits of convalescent plasma treatment compared to placebo or no treatment and all-cause mortality in patients with COVID-19, using data from all available randomized clinical trials, including unpublished and ongoing trials (Open Science Framework, https://doi.org/10.17605/OSF.IO/GEHFX ). Methods In this collaborative systematic review and meta-analysis, clinical trial registries (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform), the Cochrane COVID-19 register, the LOVE database, and PubMed were searched until April 8, 2021. Investigators of trials registered by March 1, 2021, without published results were contacted via email. Eligible were ongoing, discontinued and completed randomized clinical trials that compared convalescent plasma with placebo or no treatment in COVID-19 patients, regardless of setting or treatment schedule. Aggregated mortality data were extracted from publications or provided by investigators of unpublished trials and combined using the Hartung–Knapp–Sidik–Jonkman random effects model. We investigated the contribution of unpublished trials to the overall evidence. Results A total of 16,477 patients were included in 33 trials (20 unpublished with 3190 patients, 13 published with 13,287 patients). 32 trials enrolled only hospitalized patients (including 3 with only intensive care unit patients). Risk of bias was low for 29/33 trials. Of 8495 patients who received convalescent plasma, 1997 died (23%), and of 7982 control patients, 1952 died (24%). The combined risk ratio for all-cause mortality was 0.97 (95% confidence interval: 0.92; 1.02) with between-study heterogeneity not beyond chance (I2 = 0%). The RECOVERY trial had 69.8% and the unpublished evidence 25.3% of the weight in the meta-analysis. Conclusions Convalescent plasma treatment of patients with COVID-19 did not reduce all-cause mortality. These results provide strong evidence that convalescent plasma treatment for patients with COVID-19 should not be used outside of randomized trials. Evidence synthesis from collaborations among trial investigators can inform both evidence generation and evidence application in patient care

Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

Abstract Background Convalescent plasma has been widely used to treat COVID-19 and is under investigation in numerous randomized clinical trials, but results are publicly available only for a small number of trials. The objective of this study was to assess the benefits of convalescent plasma treatment compared to placebo or no treatment and all-cause mortality in patients with COVID-19, using data from all available randomized clinical trials, including unpublished and ongoing trials (Open Science Framework, https://doi.org/10.17605/OSF.IO/GEHFX ). Methods In this collaborative systematic review and meta-analysis, clinical trial registries (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform), the Cochrane COVID-19 register, the LOVE database, and PubMed were searched until April 8, 2021. Investigators of trials registered by March 1, 2021, without published results were contacted via email. Eligible were ongoing, discontinued and completed randomized clinical trials that compared convalescent plasma with placebo or no treatment in COVID-19 patients, regardless of setting or treatment schedule. Aggregated mortality data were extracted from publications or provided by investigators of unpublished trials and combined using the Hartung–Knapp–Sidik–Jonkman random effects model. We investigated the contribution of unpublished trials to the overall evidence. Results A total of 16,477 patients were included in 33 trials (20 unpublished with 3190 patients, 13 published with 13,287 patients). 32 trials enrolled only hospitalized patients (including 3 with only intensive care unit patients). Risk of bias was low for 29/33 trials. Of 8495 patients who received convalescent plasma, 1997 died (23%), and of 7982 control patients, 1952 died (24%). The combined risk ratio for all-cause mortality was 0.97 (95% confidence interval: 0.92; 1.02) with between-study heterogeneity not beyond chance (I2 = 0%). The RECOVERY trial had 69.8% and the unpublished evidence 25.3% of the weight in the meta-analysis. Conclusions Convalescent plasma treatment of patients with COVID-19 did not reduce all-cause mortality. These results provide strong evidence that convalescent plasma treatment for patients with COVID-19 should not be used outside of randomized trials. Evidence synthesis from collaborations among trial investigators can inform both evidence generation and evidence application in patient care